Comments
A public meeting is scheduled by the US Food and Drug Administration on April 20 and 21 to evaluate the FDA’s regulatory framework on homoeopathic products. The hearing seeks to obtain information and comments from stakeholders about the current use of human drug and biological products labelled as homeopathic, as well as the Agency’s regulatory framework for such products, including prescription drugs and biological products besides over-the-counter (OTC) drugs — labeled homeopathic. FDA is seeking participants for the public hearing and written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, healthcare professionals, patient groups, and industry, the US regulator said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.